About Keratin, type II cytoskeletal 72
Keratin, type II cytoskeletal 72 (KRT72) is a protein
from Homo sapiens identified by UniProt accession
Q14CN4, 511 residues long.
MolForge cross-references it against 0 known binders and
58 disease associations.
Target properties
| Protein name | Keratin, type II cytoskeletal 72 |
| UniProt accession | Q14CN4 |
| Gene | KRT72 |
| Organism | Homo sapiens |
| Length | 511 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (58)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.28
- head and neck squamous cell carcinoma · score 0.19
- ovarian cancer · score 0.18
- clear cell renal carcinoma · score 0.18
- breast adenocarcinoma · score 0.18
- appendicitis · score 0.14
- esophageal cancer · score 0.14
- disorder of appendix · score 0.12
- psoriasis · score 0.06
- Testicular regression syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14CN4-F1 | alphafold | PREDICTED | 70.65 | — |
Amino-acid sequence (511 residues)
MSRQLTHFPR GERLGFSGCS AVLSGGIGSS SASFRARVKG SASFGSKSLS CLGGSRSLAL SAAARRGGGR LGGFVGTAFG SAGLGPKCPS VCPPGGIPQV TVNKSLLAPL NVEMDPEIQR VRAQEREQIK ALNNKFASFI DKVRFLEQQN QVLETKWNLL QQLDLNNCRK NLEPIYEGYI SNLQKQLEML SGDGVRLDSE LRNMQDLVED YKKRYEVEIN RRTAAENEFV VLKKDVDAAY MNKVELQAKV DSLTDEIKFF KCLYEGEITQ IQSHISDTSI VLSMDNNRDL DLDSIIAEVR AQYEEIALKS KAEAETLYQT KIQELQVTAG QHGDDLKLTK AEISELNRLI QRIRSEIGNV KKQCADLETA IADAEQRGDC ALKDARAKLD ELEGALHQAK EELARMLREY QELVSLKLAL DMEIATYRKL LESEECRMSG EYPNSVSISV ISSTNAGAGG AGFSMGFGAS SSYSYKTAAA DVKTKGSCGS ELKDPLAKTS GSSCATKKAS R
Explore Keratin, type II cytoskeletal 72 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets